 Shares of CureVac CVAC, 0.47 were up 1.2 in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine its developing with GlaxoSmithKline GSK, -0.18 . The study is being conducted in the U.S. and is set to enroll 210 adults. 